At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
PCI-32765drug
Likely dose
PCI-32765 420 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating PCI-32765 for B-cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Completed, enrolled 133 participants across 10 sites.
Detailed Summary
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionDec 2012
Study CompletionFeb 2013
TodayJul 2026
First PostedApr 16, 2010
Enrollment StartMay 1, 2010
Primary CompletionDec 1, 2012
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.2 years ago
Interventions
PCI-32765drug
420 mg daily or 840 mg daily